Simon Khagi

Oncology

1 Hoag Dr Bldg 41
Newport Beach, CA 92663

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial.

Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial.

Journal: medRxiv : the preprint server for health sciences

Published: July 03, 2026

Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.

Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.

Journal: Nature medicine

Published: July 21, 2025

Intracranial Activity of Sotorasib in KRASG12C-Mutated Recurrent Glioblastoma.

Intracranial Activity of Sotorasib in KRASG12C-Mutated Recurrent Glioblastoma.

Journal: JCO precision oncology

Published: April 03, 2025

Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial.

Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial.

Journal: Cancer

Published: August 31, 2024

Recent advances in Tumor Treating Fields (TTFields) therapy for glioblastoma.

Recent advances in Tumor Treating Fields (TTFields) therapy for glioblastoma.

Journal: The oncologist

Published: March 16, 2024

Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.

Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.

Journal: JAMA oncology

Published: November 17, 2022

Paraneoplastic Optic Neuropathy in a Patient With Glioblastoma.

Paraneoplastic Optic Neuropathy in a Patient With Glioblastoma.

Journal: Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society

Published: September 27, 2022

Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.

Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.

Journal: Nature medicine

Published: August 20, 2022

Fibrin gel enhances the antitumor effects of chimeric antigen receptor T cells in glioblastoma.

Fibrin gel enhances the antitumor effects of chimeric antigen receptor T cells in glioblastoma.

Journal: Science advances

Published: October 06, 2021

Response to Selpercatinib in a Patient With Recurrent Glioblastoma and RET Amplification.

Response to Selpercatinib in a Patient With Recurrent Glioblastoma and RET Amplification.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: August 04, 2021

Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement.

Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 28, 2021

Use of FLOSEAL® as a scaffold and its impact on induced neural stem cell phenotype, persistence, and efficacy.

Use of FLOSEAL® as a scaffold and its impact on induced neural stem cell phenotype, persistence, and efficacy.

Journal: Bioengineering & translational medicine

Published: June 17, 2021

Showing 1-12 of 29

Last Updated: 09/26/2026